Yuval Avni
Partner @ Giza Venture Capital
Hadera, Israel
Yuval Avni is a seed investor at Giza Venture Capital in Hadera focused on Medical and Health Care. Yuval Avni is the Managing General Partner at Crescendo venture partners.He attended Technion - Israel Institute of Technology.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Yuval Avni invests in
Stages Yuval Avni invests in
Countries Yuval Avni invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (40%)
- Health Care 2 (40%)
- Medical Device 2 (40%)
- mHealth 1 (20%)
- Biotechnology 1 (20%)
Stage
- Seed 1 (20%)
- Series A 1 (20%)
- Series C 1 (20%)
- Series D 1 (20%)
- Series E 1 (20%)
Country
- Israel 2 (40%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Alison is the world's best AI-powered creative (Video) Analysis platform. From ideation to optimization to production, Alison makes it easier than ever to create Videos with the highest likelihood of success.Our unique SaaS technology allows businesses to identify their top-performing elements in creatives, get full-funnel data, and performintelligent competitive analysis. Stop the guesswork and start making results-driven creatives! | $13.3M / Seed / Nov 12, 2024 | ||
| Reimagining Healthcare with AI-Driven Patient Journeys Datos Health is revolutionizing the way healthcare is delivered by empowering providers with an AI-powered platform to design and implement smart, scalable hybrid and remote care solutions. Our advanced automation capabilities optimize care delivery, streamline operations, and enhancecapacity—allowing healthcare teams to focus on delivering exceptional patient care. Key Benefits: 1. AI-Powered Automation: Scale personalized patient journeys with ease while reducing manual tasks and improving efficiency. 2. Enhanced Care Capacity: Maximize resources and serve more patients effectively, prioritizing complex cases. 3. Seamless Device Integration: Enable real-time data monitoring for proactive, evidence-based interventions. 4. Advanced Outcome Tracking: Leverage PROMs/ePROs to collect actionable insights and continuously refine care plans. 5. Engaged Patient Experience: Empower patients with personalized education and support for improved adherence and outcomes. 6. Integrated Virtual Care: Facilitate seamless provider-patient interactions with accessible virtual visits. Datos Health is driving the future of hybrid care, offering providers the tools they need to unlock better patient outcomes, greater efficiency, and smarter care. | $7M / Series A / Apr 07, 2020 | ||
| LifeBond is a leader in the development and manufacturing of bio-surgical medical devices for tissue repair that are intended to improve the recovery of patients and to create an environment that supports the body’s natural healing process and promotes tissue repair. Of natural origin, elastic, adhesive, durable and yet absorbable, the company’sdevices can be used to fill a long list of unmet surgical needs. LifeBond’s first product, LifeSeal™, is designed to provide staple-line reinforcement in bariatric and colorectal operations. It was recently studied in an international pilot clinical study in Europe. The company’s second pipeline product, LifeMesh™, a self-fixating hernia mesh, is in pre-clinical development. Other pipeline products include tissue adhesives and absorbable hemostats. LifeSeal™, LifeMesh™ and other LifeBond™ products are investigational and have not yet been approved for sale in the US or in any other market. For more information please visit use at: www.life-bond.com | $27M / Series D / Aug 05, 2015 | ||
| LifeBond is a leader in the development and manufacturing of bio-surgical medical devices for tissue repair that are intended to improve the recovery of patients and to create an environment that supports the body’s natural healing process and promotes tissue repair. Of natural origin, elastic, adhesive, durable and yet absorbable, the company’sdevices can be used to fill a long list of unmet surgical needs. LifeBond’s first product, LifeSeal™, is designed to provide staple-line reinforcement in bariatric and colorectal operations. It was recently studied in an international pilot clinical study in Europe. The company’s second pipeline product, LifeMesh™, a self-fixating hernia mesh, is in pre-clinical development. Other pipeline products include tissue adhesives and absorbable hemostats. LifeSeal™, LifeMesh™ and other LifeBond™ products are investigational and have not yet been approved for sale in the US or in any other market. For more information please visit use at: www.life-bond.com | $20M / Series C / May 23, 2011 | ||
| VisionCare Ophthalmic Technologies, Inc., a Saratoga, CA-based developer of advanced visual prosthetic devices designed to improve vision in patients with end-stage age-related macular degeneration (AMD).VisionCare Ophthalmic Technologies (VisionCare) is a privately held specialty medical device company engaged in the research, development,manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders.Our lead product, the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), is the first FDA-approved implantable medical device demonstrated to improve vision and quality of life in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD) – End-Stage AMD. End-Stage AMD is the leading cause of blindness in older Americans.The telescope implant is integral to the CentraSight™ treatment program which has been developed to help patients follow the necessary steps for proper diagnosis, surgical evaluation, and postoperative care.Our goal is to help patients reconnect to the things in life they love to see and do. To help achieve this, we will establish a high level of collaboration with our healthcare provider customers through a broad range of direct support programs and services. | $31M / Series E / Jan 10, 2011 |
Co-Investors
About Giza Venture Capital
Giza Venture Capital, established in 1992, is a pioneer investor in seed and early-stage technology companies and currently manages five funds totaling over $600 million. Giza has invested in over 90 companies in the sectors of Communications, Information Technology, Enterprise Software, Life Sciences, Internet and New Media. Giza's visionin recognizing future technology leaders has led to over 30 successful exits. Giza also has a seed stage investment plan called the Ofek Program whose goal is to secure investment in high-quality seed opportunities at the earliest possible stage.
Giza Venture Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Zvi Schechter
Managing Director, Co-Founder
|
|||
Ezer Soref
Venture Partner
|
|||
Moshe Nazarathy
Venture Partner
|
|||
Ravit Shaked
Investment Professional
|
|||
Shuki Erlich
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Yuval Avni invest in?
Yuval Avni invests primarily in Medical, Health Care and Medical Device startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Yuval Avni?
Public channels for Yuval Avni include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Yuval Avni last invest?
The most recent investment recorded for Yuval Avni closed in Nov 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
